Glucagon-like peptide-1 (GLP-1) peptides have emerged as a compelling therapeutic avenue for managing metabolic disorders. These naturally occurring substances are secreted by the gut in response to food intake, stimulating insulin release and suppressing glucagon release. GLP-1 peptides exhibit promising therapeutic outcomes in treating type 2 dia